Net profit of Natco Pharma rose 40.07% to Rs 386.30 crore in the quarter ended March 2024 as against Rs 275.80 crore during the previous quarter ended March 2023. Sales rose 18.98% to Rs 1068.30 crore in the quarter ended March 2024 as against Rs 897.90 crore during the previous quarter ended March 2023.For the full year,net profit rose 94.09% to Rs 1388.30 crore in the year ended March 2024 as against Rs 715.30 crore during the previous year ended March 2023. Sales rose 47.72% to Rs 3998.80 crore in the year ended March 2024 as against Rs 2707.10 crore during the previous year ended March 2023. ParticularsQuarter EndedYear Ended�Mar. 2024Mar. 2023% Var.Mar. 2024Mar. 2023% Var. Sales1068.30897.90 19 3998.802707.10 48 OPM %46.5537.77 -43.8034.56 - PBDT533.10365.40 46 1860.301025.70 81 PBT477.60324.40 47 1673.50861.90 94 NP386.30275.80 40 1388.30715.30 94 Powered by Capital Market - Live News

Natco Pharma will hold a meeting of the Board of Directors of the Company on 27 May 2024Powered by Capital Market - Live News

NATCO Pharma announced that Fresenius Kabi USA, LLC and Fresenius Kabi Deutschland GmbH (together, �Fresenius�) have filed a complaint against Natco Pharma USA LLC f/k/a Dash Pharmaceuticals LLC in the District Court of Delaware relating to the marketing of Dash Pharmaceuticals Diazepam Injection prefilled syringe in the United States. Fresenius has not yet effectuated service of the complaint which is required to commence the lawsuit. Natco Pharma intends to defend the matter accordingly. Dash Pharmaceuticals LLC had been acquired by Natco Pharma, Inc. and Dash Pharmaceuticals LLC had changed its name to Natco Pharma USA LLCPowered by Capital Market - Live News

Natco Pharma has received a warning letter dated 08 April 2024 from the United States Food and Drug Administration (USFDA) for its Kothur (Pharma Division) manufacturing facility. The Company does not believe that the warning letter will have an impact on disruption of supplies or existing revenues from this facility. It may cause delay/withholding of pending product approvals from this site.Powered by Capital Market - Live News

Net profit of Natco Pharma rose 241.41% to Rs 212.70 crore in the quarter ended December 2023 as against Rs 62.30 crore during the previous quarter ended December 2022. Sales rose 54.03% to Rs 758.60 crore in the quarter ended December 2023 as against Rs 492.50 crore during the previous quarter ended December 2022. ParticularsQuarter Ended�Dec. 2023Dec. 2022% Var. Sales758.60492.50 54 OPM %35.3421.50 - PBDT300.50122.90 145 PBT256.3081.40 215 NP212.7062.30 241 Powered by Capital Market - Live News